The private-label lens phenomenon

Article

Several members of the lens industry came together Friday during a forum at Vision Expo East to discuss the rising trend of private-label progressive lenses.

New York City-Several members of the lens industry came together Friday during a forum at Vision Expo East to discuss the rising trend of private-label progressive lenses.

There are currently over 100 private-label designs on the U.S. market. As the market continues to expand, managed care will have to contend with these private-label lenses and lens casters will play a more aggressive role.

“Managed care has become a cancer, for lack of a better term. I’m not afraid to say it. The stronger and the bigger they get, we become slaves to managed care and until we stand up and say we’re not going take it anymore, they’re going to continue,” says Lloyd Yazbek, president of Central One Optical, a laboratory in Youngstown, OH. But, he says, managed care plans will be pressured into private-label lenses.

With the development of free-form lens processing technology, lenses can be personalized for individual patients.

Private-label, free-form lenses offer:

• Flexibility for the lab

• Price tier potential for the ECP

• Strong profit margins for both the lab and ECP

• Competitive advantage

• Quality designs

“The bad rap on free-form is that people think it’s a cheap lens-it’s not a cheap lens,” says Yazbek.

If an eyecare professional wants to start selling private-label lenses, Michael Palkovicz, president of I-See Optical laboratory in Blackwood, NJ, says marketing and staff education are the most important factors.

“When you market it in your practice, you market it as the best-that it is able to be designed to meet the needs of that patient,” says Yazbek.

Kurt Gardner, national sales and support manager for Indizen Optical Technologies, says that ECPs are faced with an immense amount of competition, so they should play up the exclusivity of the product.

“You’re building your practice brand on the brand of the laboratory,” says Gardner.

At the same time, Gardner warned, “You don’t want to over-promise. There’s no such thing as the perfect progressive, although we’re trying.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
© 2025 MJH Life Sciences

All rights reserved.